Verrica Pharmaceuticals Aktie

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
December 6, 2024 6:15am

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, PA – December 6, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.
https://verrica.com/press_release/verrica-pharmaceuticals-announces-that-development-partner-torii-pharmaceutical-files-new-drug-application-of-to-208-the-treatment-of-molluscum-contagiosum-in-japan/

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

March 17, 2021 07:00 ET |

We are excited to partner with Verrica and add VP-102 to Torii’s growing portfolio of products to treat dermatologic skin diseases with significant unmet need,” said Goichi Matsuda, Torii’s Representative Director, President and Chief Executive Officer. “VP-102 has the potential to alleviate the burden of molluscum and common warts for patients in Japan. We look forward to partnering with Verrica and developing VP-102 for the Japanese market.”

In August 2020 Verrica entered into an Option Agreement with Torii granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum and common warts in Japan, including VP-102. Torii exercised its option to acquire the exclusive license on March 2, 2021. Under the terms of the License Agreement, Torii will make an up-front payment of $11.5 million and up to an additional $58 million in aggregate payments contingent on achievement of specified development, regulatory, and sales milestones, in addition to tiered transfer price payments for supply of product in the percentage range of the mid-30s to the mid-40s of net sales. Torii is responsible for all development activities and costs in support of obtaining regulatory approval in Japan.

https://www.globenewswire.com/news-release/2021/03/17/2194392/0/en/Verrica-Pharmaceuticals-Announces-Exclusive-Licensing-Agreement-With-Torii-Pharmaceutical-Co-Ltd-To-Develop-and-Commercialize-VP-102-For-Molluscum-and-Common-Warts-in-Japan.html

RBC Capital revidierte seine Prognose für Verrica und senkte das Kursziel der Aktie von 14 auf 13 US-Dollar, behielt aber die Einstufung "Outperform" bei. Diese Anpassung folgte auf Herausforderungen bei der Markteinführung von YCANTH, Verricas Behandlung für Molluscum contagiosum.

Zuletzt meldete Verrica positive vorläufige Open-Label-Phase-II-Daten von VP-315 zur Behandlung von Basalzellkarzinom. Die Studie berichtete von einer vollständigen Beseitigung bei 51% der behandelten Läsionen, was die Erwartungen des Managements übertraf.Weitere Einblicke in das klinische Profil von VP-315 werden voraussichtlich im ersten Quartal 2025 enthüllt. Dies sind die jüngsten Entwicklungen für Verrica Pharmaceuticals.

https://de.investing.com/news/company-news/needham-stuft-verricaaktie-herab-umsatzkurzungen-und-fuhrungswechsel-wecken-bedenken-93CH-2723759

Mit einem Q3 Verlust von 23 Mio. $ bei einem Cashbestand von 23 Mio. $ sieht die Cashreichweite sehr limitiert aus. Die Ankündigung „Strategien zur Stärkung der Bilanz zu überprüfen“ kommt reichlich spät.

https://investors.verrica.com/news-releases/news-release-details/verrica-pharmaceuticals-reports-third-quarter-2024-financial